RAIL vs XFOR Comparison

FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs primarily in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. Its clientele includes shippers, railroads, and financial institutions. The company has two segments: Manufacturing and Parts. The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and major rebuilds, while the Parts segment, along with corporate activities, constitutes Corporate and Other. The company's revenue is predominantly derived from its Manufacturing segment, with all revenue generated within the United States.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.